Theravance Announces Presentation of GSK Phase 2 Data for LAMA at CHEST 2011

Theravance, Inc.

today announced that data from a GlaxoSmithKline

Phase 2b study of GSK573719, a long-acting muscarinic antagonist (LAMA), in patients with chronic obstructive pulmonary disease, will be presented at CHEST 2011. The annual meeting of the American College of Chest Physicians, takes place on October 22-26, 2011 in Honolulu, Hawaii. GSK573719 is the LAMA component in LAMA/LABA (GSK573719/Vilanterol), an investigational product being developed by GSK under the LABA collaboration between GSK and Theravance. Results for the 14-day crossover Phase 2b study that evaluated lung function following multiple dosages of GSK573719 monotherapy will be presented on October 26, 2011. The presentation is embargoed until 12:45 PM HST on October 26, 2011.